{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-071517","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.681350+00:00","generated_at":"2026-05-16T00:19:43.194128+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Revolution Medicines FY2025 net loss $1.1B; daraxonrasib Phase 3 readout on track for H1 2026","bullets":["Full year 2025 net loss $1.1B vs $600.1M in 2024; Q4 net loss $364.9M vs $194.6M.","Cash $2.0B; 2026 GAAP op expenses guided $1.6-$1.7B with $180-$200M stock comp.","Phase 3 RASolute 302 (daraxonrasib in 2L PDAC) readout expected H1 2026; enrollment complete.","Initiated RASolute 305 (zoldonrasib in 1L PDAC); zoldonrasib FDA Breakthrough Therapy in NSCLC.","New RAS(ON) inhibitor RMC-5127 entered clinic; new class RM-055 Phase 1 planned Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-071517","json":"https://secwatch.observer/filing/0001193125-26-071517.json","markdown":"https://secwatch.observer/filing/0001193125-26-071517.md","text":"https://secwatch.observer/filing/0001193125-26-071517.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000119312526071517/0001193125-26-071517-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000119312526071517/rvmd-20260225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:19:43.194128+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}